许多钌(Ⅱ)配合物在水溶液中可以发生光诱导配体解离,形成的水合物能够与DNA共价结合.Ru(Ⅱ)配合物的这一特性近年来在抗癌药物研发领域被利用来发展新型光活化化疗试剂.通过合理选择配体和调控配位构型,光活化化疗试剂可以实现抗癌活性物种在肿瘤组织的高选择性且计量可控的释放,有希望在提高药物疗效的同时降低其毒副作用.本文对近年来钌(Ⅱ)光活化化疗试剂的研究进展做了全面的综述,并展望了该领域的未来发展方向. Many of the complexes of ruthenium (Ⅱ) can dissociate with light-induced ligands in aqueous solution and the formed hydrates can covalently bind with DNA. This property of Ru (Ⅱ) complexes has been used in the field of anticancer drug discovery in recent years To develop a new type of photo-activated chemotherapeutic agents.Through the rational choice of ligands and regulation of coordination configuration, photoactivated chemotherapeutic agents can achieve highly selective and measurable release of anticancer active species in tumor tissues, and hopefully to improve the efficacy of the drug While reducing their toxic side effects.In this paper, we reviewed the research progress of ruthenium (Ⅱ) photochemically activated chemotherapeutic agents in recent years and looked forward to the future development of this field.